Equities Analysts Set Expectations for MaxCyte, Inc.’s Q1 2025 Earnings (NASDAQ:MXCT)

MaxCyte, Inc. (NASDAQ:MXCT) – William Blair issued their Q1 2025 earnings per share estimates for shares of MaxCyte in a research note issued to investors on Wednesday, May 8th. William Blair analyst M. Larew expects that the company will post earnings of ($0.14) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for MaxCyte’s current full-year earnings is ($0.53) per share. William Blair also issued estimates for MaxCyte’s Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.13) EPS and Q4 2025 earnings at ($0.13) EPS.

MaxCyte (NASDAQ:MXCT) last issued its earnings results on Tuesday, March 12th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.05. The company had revenue of $15.67 million during the quarter, compared to the consensus estimate of $15.60 million. MaxCyte had a negative return on equity of 15.90% and a negative net margin of 91.85%.

MXCT has been the topic of several other research reports. BTIG Research lowered their price objective on MaxCyte from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, March 13th. Stephens reaffirmed an “overweight” rating and set a $11.00 price target on shares of MaxCyte in a research report on Tuesday, April 23rd.

MaxCyte Stock Down 8.9 %

Shares of NASDAQ:MXCT opened at $4.31 on Friday. The business has a 50 day moving average of $4.10 and a 200-day moving average of $4.37. The stock has a market cap of $450.58 million, a PE ratio of -12.78 and a beta of 1.36. MaxCyte has a 12-month low of $2.45 and a 12-month high of $5.55.

Hedge Funds Weigh In On MaxCyte

Hedge funds have recently added to or reduced their stakes in the stock. Cadian Capital Management LP bought a new position in shares of MaxCyte in the fourth quarter worth $26,531,000. Massachusetts Financial Services Co. MA increased its holdings in MaxCyte by 29.9% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 2,537,114 shares of the company’s stock valued at $11,924,000 after buying an additional 584,372 shares during the period. River Global Investors LLP raised its position in shares of MaxCyte by 24.4% in the 1st quarter. River Global Investors LLP now owns 1,888,642 shares of the company’s stock valued at $7,973,000 after buying an additional 369,996 shares in the last quarter. Mudita Advisors LLP lifted its holdings in shares of MaxCyte by 35.3% during the 4th quarter. Mudita Advisors LLP now owns 1,881,349 shares of the company’s stock worth $8,842,000 after acquiring an additional 490,491 shares during the period. Finally, Chevy Chase Trust Holdings LLC boosted its position in shares of MaxCyte by 2,182.6% during the 1st quarter. Chevy Chase Trust Holdings LLC now owns 1,296,397 shares of the company’s stock worth $5,432,000 after acquiring an additional 1,239,602 shares in the last quarter. Institutional investors own 68.81% of the company’s stock.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.